Phio Pharmaceuticals Reports Positive Phase 1b Trial Results

The latest update is out from Phio Pharmaceuticals ( (PHIO) ).

On May 7, 2025, Phio Pharmaceuticals announced positive pathology results from the third cohort of its ongoing Phase 1b clinical trial evaluating the safety and tolerability of INTASYL PH-762 for skin cancer treatment. Two out of three patients with cutaneous squamous cell carcinoma achieved complete pathologic response, indicating potential as a non-surgical alternative in the expanding skin cancer market. The trial, which has treated 10 patients to date, demonstrated no dose-limiting toxicities, supporting continued dose escalation and enrollment expected to complete in the third quarter of 2025.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology. The company aims to enhance the body’s immune cells to more effectively kill cancer cells, with its lead clinical program being PH-762, a compound that silences the PD-1 gene implicated in various forms of skin cancer.

Average Trading Volume: 3,027,482

Technical Sentiment Signal: Strong Sell

Current Market Cap: $8.22M

For detailed information about PHIO stock, go to TipRanks’ Stock Analysis page.